Roche (OTCQX:RHHBY) is upgraded to Buy, driven by strong 2025 performance, robust pipeline, and attractive valuation metrics. RHHBY faces major patent expiries, but new launches like Phesgo, Helimbra, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback